Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.9153
-$0.0257-2.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.50% | -18.75% | -14.31% | -19.15% | -20.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.82% | 8.51% | 13.28% | 22.48% | 26.93% |
| Operating Income | 10.82% | -8.51% | -13.28% | -22.48% | -26.93% |
| Income Before Tax | 10.34% | -8.45% | -8.36% | -17.54% | -32.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.34% | -8.45% | -8.36% | -17.54% | -32.23% |
| Earnings from Discontinued Operations | -- | 98.87% | 99.11% | 91.73% | 79.45% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.89% | 1.60% | 3.63% | -2.42% | -14.53% |
| EBIT | 10.82% | -8.51% | -13.28% | -22.48% | -26.93% |
| EBITDA | 11.28% | -7.70% | -11.51% | -19.43% | -22.13% |
| EPS Basic | 1.52% | -20.74% | -15.26% | -14.29% | -19.31% |
| Normalized Basic EPS | -1.33% | -42.98% | -39.13% | -42.01% | -51.12% |
| EPS Diluted | 1.52% | -20.74% | -15.26% | -14.29% | -19.31% |
| Normalized Diluted EPS | -1.33% | -42.98% | -39.13% | -42.01% | -51.12% |
| Average Basic Shares Outstanding | -13.95% | -15.09% | -12.10% | -4.58% | 3.72% |
| Average Diluted Shares Outstanding | -13.95% | -15.09% | -12.10% | -4.58% | 3.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |